{"content":[{"text":"agonists and 78% (95% CI, 72.4%-83.4%) of children who initiated stimulants. Only \n daytime sleepiness was more common for those receiving α2-adrenergic agonists vs \n stimulants (38% vs 3%); several adverse effects were reported more commonly for those \n receiving stimulants vs α2-adrenergic agonists, including moodiness/irritability (50% vs \n 29%), appetite suppression (38% vs 7%), and difficulty sleeping (21% vs 11%).","bbox":{"left":0.095243,"top":0.06891,"width":0.7916000000000001,"height":0.09003899999999998}},{"text":"Conclusions and relevance: In this retrospective review of health records of preschool-age \n children with ADHD treated in developmental-behavioral pediatric practices, improvement \n was noted in the majority of children who received α2-adrenergic agonists or stimulants, \n with differing adverse effect profiles between medication classes. Further research, \n including from randomized clinical trials, is needed to assess comparative effectiveness of \n α2-adrenergic agonists vs stimulants.","bbox":{"left":0.095243,"top":0.180084,"width":0.803188,"height":0.108569}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}